Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00536172 · ClinicalTrials.gov registry record · Phase 4
Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment
A Phase 4 study of Depression, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 4
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT00536172 is a Phase 4 study of Depression that has completed, run by University of Nebraska. The registered enrollment target is 160 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00536172, a Phase 4 study of Depression, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effectiveness of escitalopram to prevent depression in head and neck cancer patients receiving treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Escitalopram
Study Locations (1)
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2007-12-01 |
| Est. Completion | 2012-06-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00536172
The ClinicalTrials.gov registry entry for NCT00536172 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (80% lower). The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00536172 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT00536172 about?
NCT00536172 is a clinical study titled "Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment". This study will evaluate the effectiveness of escitalopram to prevent depression in head and neck cancer patients receiving treatment.
What is the current status of trial NCT00536172?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 160 participants. The study started on 2007-12-01. Estimated completion is 2012-06-01.
What conditions does trial NCT00536172 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT00536172?
The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00536172?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00536172 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.